These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 7612229)

  • 1. Paracrine cytokine adjuvants in cancer immunotherapy.
    Pardoll DM
    Annu Rev Immunol; 1995; 13():399-415. PubMed ID: 7612229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
    Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.
    Golumbek PT; Azhari R; Jaffee EM; Levitsky HI; Lazenby A; Leong K; Pardoll DM
    Cancer Res; 1993 Dec; 53(24):5841-4. PubMed ID: 8261390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine and immuno-gene therapy for solid tumors.
    Li CY; Huang Q; Kung HF
    Cell Mol Immunol; 2005 Apr; 2(2):81-91. PubMed ID: 16191413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.
    Ferrone CR; Perales MA; Goldberg SM; Somberg CJ; Hirschhorn-Cymerman D; Gregor PD; Turk MJ; Ramirez-Montagut T; Gold JS; Houghton AN; Wolchok JD
    Clin Cancer Res; 2006 Sep; 12(18):5511-9. PubMed ID: 17000687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cellular and cytokine adjuvants in the immunotherapy of cancer.
    Salgaller ML; Lodge PA
    J Surg Oncol; 1998 Jun; 68(2):122-38. PubMed ID: 9624043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response.
    Nguyen CL; Bui JT; Demcheva M; Vournakis JN; Cole DJ; Gillanders WE
    J Immunother; 2001; 24(5):420-9. PubMed ID: 11696697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.
    Chiang CL; Kandalaft LE; Coukos G
    Int Rev Immunol; 2011; 30(2-3):150-82. PubMed ID: 21557641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokines as an adjuvant to tumor vaccines: efficacy of local methods of delivery.
    Kurane S; Arca MT; Aruga A; Krinock RA; Krauss JC; Chang AE
    Ann Surg Oncol; 1997; 4(7):579-85. PubMed ID: 9367025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.
    Lathuilière A; Mach N; Schneider BL
    Int J Mol Sci; 2015 May; 16(5):10578-600. PubMed ID: 26006227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens.
    Disis ML; Shiota FM; McNeel DG; Knutson KL
    Immunobiology; 2003; 207(3):179-86. PubMed ID: 12777059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
    Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
    Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer.
    Cao X; Huang X; Ju DW; Zhang W; Hamada H; Wang J
    Cancer Gene Ther; 2000 Feb; 7(2):177-86. PubMed ID: 10770625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
    Moschella F; Proietti E; Capone I; Belardelli F
    Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of metastasis.
    Dallal RM; Lotze MT
    Surg Oncol Clin N Am; 2001 Apr; 10(2):433-47, xi. PubMed ID: 11382596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal.
    Parmiani G; Rodolfo M; Melani C
    Hum Gene Ther; 2000 Jun; 11(9):1269-75. PubMed ID: 10890737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-12 as an adjuvant for cancer immunotherapy.
    Rodolfo M; Colombo MP
    Methods; 1999 Sep; 19(1):114-20. PubMed ID: 10525447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.